Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
CAL-51 | Olaparib | PARP | Misc | 7.1917 | 0.3596 | 0.1163 | 0.0073 | 0.8214 | 27.3972 | 0.94373 |
HCC1428 | Cabozantinib | VEGFR2/MET | RTK | Inf | 0.6310 | 0.0204 | -0.0008 | 2.9241 | 4.2982 | 0.94377 |
HCC1395 | TGX221 | PI3Kb | PI3K/mTOR | 8.4625 | 0.4581 | 0.0950 | 0.0125 | 0.6815 | 16.0341 | 0.94431 |
PDX1328 | Topotecan | Topo I | Chemotherapy | 0.0059222 | -0.9128 | 1.0720 | 0.1509 | 0.4616 | 0.063175 | 0.94441 |
SUM1315MO2 | Abemaciclib | CDK4/6 | Cell cycle | 0.049304 | -0.1445 | 0.5815 | 0.0291 | 0.5067 | 0.075697 | 0.94514 |
HCC1419 | Topotecan | Topo I | Chemotherapy | 0.0071886 | -0.7857 | 0.9904 | 0.1711 | 0.4002 | 0.11192 | 0.94532 |
HCC1500 | Olaparib | PARP | Misc | 6.3506 | 0.2744 | 0.0985 | 0.0084 | 1.0887 | 17.4212 | 0.94589 |
HCC1419 | Doxorubicin | Chemo | Chemotherapy | 0.025082 | -0.4663 | 0.5904 | 0.0473 | 0.5199 | 0.10425 | 0.94593 |
HCC1954 | ABT-737 | Bcl2/XL | Misc | 9.9512 | 0.4962 | 0.0404 | 0.0618 | 1.0240 | 27.9634 | 0.94601 |
MCF 10A | A-1210477 | Mcl-1 | Misc | Inf | 0.9527 | 0.0018 | 0.0006 | 4.5125 | 3.8181 | 0.94609 |
HCC1937 | Alpelisib | PI3Ka | PI3K/mTOR | 18.8171 | 0.6577 | 0.0501 | 0.0085 | 0.8078 | 73.2808 | 0.94623 |
MDA-MB-134-VI | Ipatasertib | AKT | PI3K/mTOR | 8.0392 | 0.4925 | 0.0150 | 0.0096 | 4.9968 | 3.7717 | 0.94642 |
PDX1258 | Ipatasertib | AKT | PI3K/mTOR | 4.4024 | 0.3985 | 0.1556 | 0.0120 | 0.7553 | 1.2185 | 0.94717 |
HCC1143 | Topotecan | Topo I | Chemotherapy | 0.0094142 | -0.4304 | 0.9040 | 0.3002 | 1.1711 | 0.013874 | 0.94725 |
HCC38 | Saracatinib | SRC | MAPK/nRTK | 29.3313 | 0.6139 | 0.1013 | 0.0162 | 0.4862 | 24.1837 | 0.94737 |
BT-20 | Olaparib | PARP | Misc | 15.2735 | 0.6064 | 0.0657 | 0.0087 | 0.8235 | 57.982 | 0.94742 |
MDA-MB-134-VI | Pictilisib | pan PI3K | PI3K/mTOR | 2.6892 | -0.1516 | 0.1775 | 0.0232 | 0.9649 | 8.3966 | 0.94749 |
PDXHCI002 | Topotecan | Topo I | Chemotherapy | 0.0066461 | -0.7006 | 1.0199 | 0.1157 | 0.8130 | 0.015555 | 0.94766 |
PDX1328 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.035818 | -0.3368 | 0.6929 | 0.0612 | 0.7466 | 0.064434 | 0.94799 |
PDX1258 | Olaparib | PARP | Misc | 11.9912 | 0.5770 | 0.0287 | 0.0113 | 1.2287 | 29.2905 | 0.94883 |
MCF7 | Taxol | Chemo | Chemotherapy | 0.0013771 | -0.1059 | 0.7722 | 0.1589 | 1.1560 | 0.0016261 | 0.94939 |
MDA-MB-468 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7230 | 0.1032 | 0.0343 | 0.5264 | 0.7426 | 0.94963 |
HCC70 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0058452 | -0.5550 | 0.6451 | 0.1234 | 0.5307 | 0.026938 | 0.94991 |
SUM1315MO2 | Olaparib | PARP | Misc | 2.0295 | 0.0911 | 0.2452 | 0.0432 | 0.5075 | 17.6824 | 0.94995 |
CAL-120 | Abemaciclib | CDK4/6 | Cell cycle | 0.247 | -0.1408 | 0.4780 | 0.0849 | 0.3730 | 4.696 | 0.95026 |